Ionis' TRYNGOLZA Nears EU Approval for Severe Hypertriglyceridemia
Event summary
- CHMP recommends EU approval for TRYNGOLZA (olezarsen) in severe hypertriglyceridemia (sHTG) ahead of schedule.
- Final European Commission decision expected in Q4 2026.
- Phase 3 CORE and CORE2 studies showed 72% triglyceride reduction and 85% fewer pancreatitis events vs. placebo.
- Ionis and Sobi aim to expand TRYNGOLZA's EU market beyond its current approval for familial chylomicronemia syndrome (FCS).
The big picture
Ionis' TRYNGOLZA represents a novel RNA-targeted approach to severe hypertriglyceridemia, a condition affecting ~2 million EU patients with triglyceride levels ≥880 mg/dL. The CHMP's accelerated recommendation underscores the unmet need for therapies that reduce acute pancreatitis risk in this high-risk population. If approved, TRYNGOLZA would become the first RNA-targeted treatment for sHTG in the EU, expanding Ionis' footprint beyond its existing FCS indication.
What we're watching
- Regulatory Timing
- Whether the European Commission will finalize approval by year-end 2026 as projected.
- Commercial Execution
- How Ionis and Sobi will position TRYNGOLZA against existing sHTG treatments in the EU.
- Pipeline Leverage
- The pace at which Ionis can replicate this success with other RNA-targeted therapies.
